# US 2014/0154206 A1 · Immunity induction agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154206 A1
- Document ID: US20140154206A1
- Status: Published application
- Kind: A1
- Application number: 14/118,417
- Filed: 2012-05-18
- Published: 2014-06-05
- Earliest claimed: 2011-05-19
- Assignees: Toray Industries, Inc.
- Inventors: Akira Kurihara; Fumiyoshi Okano
- Web page: https://patentgrep.com/patent/US20140154206A1

## CPC

- C12N 9/0071: {acting on paired donors with incorporation of molecular oxygen (1.14)}
- A61K 38/20: Interleukins [IL]
- A61K 38/21: Interferons {[IFN]}
- A61K 38/44: Oxidoreductases (1)
- A61K 39/0011: {Cancer antigens}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a novel immunity-inducing agent useful as a therapeutic and/or prophylactic agent for cancer. The immunity-inducing agent comprises as an effective ingredient(s) at least one polypeptide having immunity-inducing activity selected from the polypeptides (a), (b) and (c) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, which recombinant vector(s) is/are capable of expressing the polypeptide(s) in vivo: (a) a polypeptide composed of not less than 7 consecutive amino acids in any one of the amino acid sequences of SEQ ID NOs:4, 2, 22 and 24 in SEQUENCE LISTING; (b) a polypeptide having a sequence identity of not less than 90% to the polypeptide (a) and composed of not less than 7 amino acids; and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof.

## Claims

### Claim 1

An immunity-inducing agent comprising as an effective ingredient(s) at least one polypeptide having immunity-inducing activity selected from the polypeptides (a) to (c) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding said at least one polypeptide, said recombinant vector(s) being capable of expressing said polypeptide(s) in vivo:
(a) a polypeptide composed of not less than 7 consecutive amino acids in any one of the amino acid sequences of SEQ ID NOs:4, 2, 22 and 24 in SEQUENCE LISTING;
(b) a polypeptide having a sequence identity of not less than 85% to said polypeptide (a) and composed of not less than 7 amino acids; and
(c) a polypeptide comprising said polypeptide (a) or (b) as a partial sequence thereof.

### Claim 2 (depends on 1)

The immunity-inducing agent according to claim 1, wherein said polypeptide having immunity-inducing activity is a polypeptide having the amino acid sequence of SEQ ID NO:4, 2, 22 or 24 in SEQUENCE LISTING.

### Claim 3 (depends on 1)

The immunity-inducing agent according to claim 1, which is an agent for treating antigen-presenting cells.

### Claim 4 (depends on 1)

The immunity-inducing agent according to claim 1, which is a therapeutic and/or prophylactic agent for a cancer(s).

### Claim 5 (depends on 4)

The immunity-inducing agent according to claim 4, wherein said cancer(s) is/are a cancer(s) expressing SCD1.

### Claim 6 (depends on 4)

The immunity-inducing agent according to claim 4, wherein said cancer(s) is/are breast cancer, brain tumor, colon cancer, perianal adenocarcinoma, neuroblastoma, mastocytoma, renal cancer, liver cancer, lung cancer, prostate cancer and/or leukemia.

### Claim 7 (depends on 1)

The immunity-inducing agent according to claim 1, further comprising an immunoenhancer.

### Claim 8 (depends on 7)

The immunity-inducing agent according to claim 7, wherein said immunoenhancer is at least one selected from the group consisting of Freund's incomplete adjuvant; Montanide; poly-I:C and derivatives thereof; CpG oligonucleotides; interleukin-12; interleukin-18; interferon-α; interferon-β; interferon-ω; interferon-γ; and Flt3 ligand.

### Claim 9 (depends on 2)

The immunity-inducing agent according to claim 2, which is an agent for treating antigen-presenting cells.

### Claim 10 (depends on 2)

The immunity-inducing agent according to claim 2, which is a therapeutic and/or prophylactic agent for a cancer(s).

### Claim 11 (depends on 5)

The immunity-inducing agent according to claim 5, wherein said cancer(s) is/are breast cancer, brain tumor, colon cancer, perianal adenocarcinoma, neuroblastoma, mastocytoma, renal cancer, liver cancer, lung cancer, prostate cancer and/or leukemia.

### Claim 12 (depends on 2)

The immunity-inducing agent according to claim 2, further comprising an immunoenhancer.

### Claim 13 (depends on 3)

The immunity-inducing agent according to claim 3, further comprising an immunoenhancer.

### Claim 14 (depends on 4)

The immunity-inducing agent according to claim 4, further comprising an immunoenhancer.

### Claim 15 (depends on 5)

The immunity-inducing agent according to claim 5, further comprising an immunoenhancer.

### Claim 16 (depends on 6)

The immunity-inducing agent according to claim 6, further comprising an immunoenhancer.
